Protease inhibitors are increasingly recognized as causing significant
metabolic abnormalities including hypertriglyceridaemia, hypercholest
erolaemia, insulin resistance, diabetes, and lipodystrophy(1,2). Consi
derable concern has been generated by recent reports(3) of premature c
oronary artery disease occurring in HIV-1 infected patients on proteas
e inhibitor containing regimens.